Skip to main content

Article Category

News

Article available in the folowing languages:

An Anti-inflammatory Formulation with FMO3 Suppressive Abilitites Part 2

This Section includes the Part 2 for the Above Mentioned Anti-inflammatory Formulation

Health

The selective cox-2 and pge-2 suppressor components have side effects such as possible insulin resistance, stomach tissue damage, and internal bleeding. As a result, the presence of the need for a composition for the anti-inflammatory and analgesic treatment and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art. Object of the Invention In order to eliminate the disadvantages of the state of the art, an object of the invention is to provide that the selective cox-2 and pge-2 suppressor components do not have side effects such as possible insulin resistance, stomach tissue damage, and inner bleeding. Another object of the invention is to simultaneously stimulate the production of cox-1 and pge-1. Another object of the invention is to provide an ability to protect the kidneys. Another object of the invention is to prevent the vessel thinning and the loss of bone density. Another object of the invention is to provide an increase owing to the increased cAMP, which is a result of the ability to suppress PDE4. Another object of the invention is to prevent the anti-inflammatory and analgesic side effects. In order to achieve the aforesaid advantages, the invention is a composition for the anti-inflammatory and analgesic treatment, said composition being obtained by the components selected from the group comprising 3,7-bis(2-hydroxyethyl)icaritin and 2,7-bis(2-hydroxyethyl)icaritin that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration. Detailed Description of the Invention According to the invention, 3,7-bis(2-hydroxyethyl)icaritin, which is a flavonol glycoside derivative contained by the plant family epimedium in trace amounts, features the ability to effectively suppress cox-2 and pge-2. Said suppression does not take place via a direct reversal of these two proinflammatory enzymes as in the case with currently available pge-2 and cox-2 antagonists. Said ingredient achieves the expression of cox-1 and pge-1 by an increase provided owing to the increased cAMP, which is a result of its ability to suppress PDE4. Accordingly, it is free of all the above-listed side effects of the currently available anti-inflammatory and analgesic drugs. The increase in the expression of pge-1 provides 3,7-bis(2-hydroxyethyl)icaritin with the hepatoprotective and kidney-protective property. The increase in the expression of pge-1 encourages the insulin release and the insulin sensitivity of the muscle cells. The increase in pge-1 prevents the thinning of vessels and the loss of bone density, which could be caused by long term cox-2 and pge-2 suppressor agents (as they do not simultaneously increase pge-1). The composition according to the invention contains 3,7-bis(2-hydroxyethyl)icaritin and 2,7-bis(2-hydroxyethyl)icaritin. Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight: 1-99% 3,7-bis(2-hydroxyethyl)icaritin 99-1% 2,7-bis(2-hydroxyethyl)icaritin The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations. Said invention also encompasses the use of said composition for the anti-inflammatory and analgesic treatment and the manufacture thereof for this purpose. CLAIMS 1. A composition for the anti-inflammatory and analgesic treatment, said composition being obtained by the components